Tirzepatide

• A clinical trial studying the effect of Tirzepatide in women living with endometrial cancer Pending
  2025-523877-40-00 Phase II 1 country University College Dublin
• ObStructive Sleep Apnoea ManageMent in Older AdUlts with Overweight or ObEsity: A Randomized ClinicaL Trial (SAMUEL study) Pending
  2026-525500-10-00 Phase IV 1 country Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre
• Efficacy and safety of pharmacological therapy of obesity in liver transplant candidates Pending
  2026-526044-12-00 Phase IV 1 country Institute For Clinical And Experimental Medicine
• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) Recruiting
  2025-522674-36-00 Phase III 15 countries Eli Lilly & Co.
• A Clinical Trial of Tirzepatide (LY3298176) in Subjects With Overweight or Obesity and PCOS-related Ovarian Dysfunction (PERIODS) Recruiting
  2024-515982-32-00 Phase IV 1 country Rheinische Friedrich-Wilhelms-Universitaet Bonn
• Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn’s Disease and Obesity or Overweight:… Recruiting
  2024-520210-21-00 Phase III 15 countries Eli Lilly & Co.
• A Study of LY3457263 Compared to Placebo in Participants with Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide Recruiting
  2024-520328-27-00 Phase II 2 countries Eli Lilly & Co.
• Can treatment with tirzepatide reduce alcohol intake in individuals diagnosed with schizophrenia and alcohol use disorder (DUALPSYCHIATRY) Recruiting
  2024-518608-28-00 Phase II 1 country Psykiatrisk Center Kobenhavn
• IDEAL-COR Recruiting
  2023-505270-15-00 Phase III/IV 1 country Steno Diabetes Center Copenhagen
• A Trial to Study the Safety and Efficacy of a New Drug Combination for Weight Loss While Maintaining Muscles Ended
  2024-519561-22-00 Phase II 2 countries F. Hoffmann-La Roche AG
• A Study of Tirzepatide (LY3298176) Compared with Placebo in Adults with Type 1 Diabetes and Obesity or Overweight (SURPASS-T1D-1) Ended
  2024-519684-17-00 Phase III 5 countries Eli Lilly & Co.
• A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5) Ended
  2024-511450-49-00 Phase III 2 countries Eli Lilly & Co.
• REIMAGINE 5: A research study to see how much CagriSema (1.0 mg once weekly) lowers blood sugar and body weight compared to tirzepatide (5 m… Ended
  2023-509600-15-00 Phase III 6 countries Novo Nordisk A/S
• A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) Ended
  2023-507655-30-00 Phase III 3 countries Eli Lilly & Co.
• A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes (TR… Ended
  2023-506082-60-00 Phase II 3 countries Eli Lilly & Co.
• Tirzepatide, a new drug for type 2 diabetes mellitus and obesity, as a possible treatment to modify the clinical evolution of Wolfram syndro… Ended
  2024-514909-64-00 Phase II 1 country Ospedale San Raffaele S.r.l.
• A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) Ended
  2022-500101-41-00 Phase IV 4 countries Eli Lilly Cork Limited

Showing 1–17 of 17 trials